Tevogen Inc is a healthcare enterprise engaged in biotechnology, artificial intelligence and technology, and healthcare services. Its operations focus on the development of biotechnology products, AI- and technology-based healthcare solutions, and healthcare service initiatives.
Last trade$5.77
Day change-$0.455 (-7.32%)
Day range$5.64 – $6.20
Volume1,421
Market cap$421M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$421.5M
Price / earnings
—
Price / book
-47.42×
Price / sales
—
EV / sales
—
EV / EBITDA
-20.44×
Profitability
Earnings per share
-$0.33
Return on assets
-472.48%
Return on equity
251.3%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.91×
Current ratio
0.33×
Quick ratio
0.33×
Cash ratio
0.18×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.63M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TVGN, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.38M
$2.27M
$2.5M
$2.62M
$2.74M
$7.16M
$6.53M
$2.82M
Research and development
$3.28M
$3.13M
$2.11M
$3.11M
$2.7M
$3.2M
$2.84M
$3.26M
Total operating expenses
$5.66M
$5.4M
$4.61M
$5.73M
$5.44M
$10.36M
$1.86M
$6.09M
Operating income
-$5.66M
-$5.4M
-$4.61M
-$5.73M
-$5.44M
-$10.36M
-$1.86M
-$6.09M
Interest expense
-$98.39K
$0
-$70.67K
-$62.34K
-$38.03K
$0
-$15.8K
-$12.46K
Income before taxes
-$5.76M
-$5.45M
-$4.68M
-$5.73M
-$5.5M
-$10.37M
-$9.44M
-$5.88M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$5.76M
-$5.45M
-$4.68M
-$5.73M
-$5.5M
-$10.37M
-$9.44M
-$5.88M
Net income attributable to common shareholders
-$5.76M
-$5.62M
-$5.23M
-$5.73M
-$5.5M
-$10.5M
-$5.99M
-$5.88M
EBITDA
-$5.63M
-$5.37M
-$4.23M
-$5.73M
-$5.35M
-$10.32M
-$9.08M
-$6.04M
Basic earnings per share
-$1.52
-$1.61
-$1.84
-$1.50
-$1.71
-$3.25
-$2.40
-$1.50
Diluted earnings per share
-$1.52
-$1.61
-$1.84
-$1.50
-$1.71
-$3.25
-$2.50
-$1.50
Recent news
Company coverage with links to the original publishers.
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced its 2026 Annual Meeting of Stockholders scheduled for August 24, 2026, to be held virtually. The company has set July 23, 2026 as the record date for stockholders and the deadline for submitting stockholder proposals and director nominations. Tevogen continues to focus on its three complementary initiatives: Tevogen Bio (biotechnology), Tevogen.AI (artificial intelligence and technology), and Tevogen Healthcare Services, aimed at improving affordability and accessibility of life-saving medicines.
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it has signed a non-binding Letter of Intent to evaluate acquiring a Management Services Organization (MSO). If completed, the transaction could expand Tevogen's healthcare infrastructure and support its evolution into a revenue-generating enterprise with combined annual revenue of approximately $100 million, alongside its biotechnology and AI technology arms.
Tevogen Bio Holdings Inc. announced capital discipline measures including its lead investor Dr. Manmohan Patel's commitment to maintain shareholdings, a pledge to limit share utilization to 1% of authorized shares over the next 12 months or until cash-flow positive, and evaluation of acquisitions that could generate over $50 million in combined annual revenue. The company is also exploring ways to better reflect the value of its assets and continues to evaluate a potential special cash dividend.
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced progress on TVGN 489, its investigational T-cell therapy for Long COVID, following the appointment of a new leadership team on March 9, 2026. The company expanded HLA target coverage to reach 65% of the U.S. population and is evaluating the acquisition of Sciometrix's Clinicus platform for real-world patient monitoring. Proof-of-concept data showed 100% of treated high-risk patients did not develop Long COVID.
Tevogen Bio Holdings (NASDAQ:TVGN) announced a non-binding Letter of Intent to explore acquiring Apozeal Pharmaceutical Inc. to strengthen its generics platform and enhance pharmaceutical affordability. The stock surged to $10.8 before falling, and is now trading at a 52-week low of $6.56, down 15.41% on the day. The company also approved a 50-for-1 reverse stock split and is considering other life sciences transactions.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.